Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 131

1.

Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.

Sane S, Rezvani K.

Int J Mol Sci. 2017 Feb 17;18(2). pii: E442. doi: 10.3390/ijms18020442. Review.

2.

The nucleoside analog clitocine is a potent and efficacious readthrough agent.

Friesen WJ, Trotta CR, Tomizawa Y, Zhuo J, Johnson B, Sierra J, Roy B, Weetall M, Hedrick J, Sheedy J, Takasugi J, Moon YC, Babu S, Baiazitov R, Leszyk JD, Davis TW, Colacino JM, Peltz SW, Welch EM.

RNA. 2017 Apr;23(4):567-577. doi: 10.1261/rna.060236.116. Epub 2017 Jan 17.

PMID:
28096517
3.

MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.

Qi DL, Cobrinik D.

Oncogene. 2017 Mar 30;36(13):1760-1769. doi: 10.1038/onc.2016.350. Epub 2016 Oct 17.

4.

p53 in the game of transposons.

Wylie A, Jones AE, Abrams JM.

Bioessays. 2016 Nov;38(11):1111-1116. doi: 10.1002/bies.201600115. Epub 2016 Sep 19.

PMID:
27644006
5.

Sustained p16INK4a expression is required to prevent IR-induced tumorigenesis in mice.

Palacio L, Krishnan V, Le NL, Sharpless NE, Beauséjour CM.

Oncogene. 2017 Mar 2;36(9):1309-1314. doi: 10.1038/onc.2016.298. Epub 2016 Aug 29.

PMID:
27568978
6.

An extra copy of p53 suppresses development of spontaneous Kras-driven but not radiation-induced cancer.

Moding EJ, Min HD, Castle KD, Ali M, Woodlief L, Williams N, Ma Y, Kim Y, Lee CL, Kirsch DG.

JCI Insight. 2016 Jul 7;1(10). pii: e86698.

7.

Lysines in the tetramerization domain of p53 selectively modulate G1 arrest.

Beckerman R, Yoh K, Mattia-Sansobrino M, Zupnick A, Laptenko O, Karni-Schmidt O, Ahn J, Byeon IJ, Keezer S, Prives C.

Cell Cycle. 2016 Jun 2;15(11):1425-38. doi: 10.1080/15384101.2016.1170270. Epub 2016 May 21.

8.

Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction.

Thayer KM, Beyer GA.

PLoS One. 2016 Mar 18;11(3):e0147806. doi: 10.1371/journal.pone.0147806. eCollection 2016.

9.

p19(Arf) is required for the cellular response to chronic DNA damage.

Bieging-Rolett KT, Johnson TM, Brady CA, Beaudry VG, Pathak N, Han S, Attardi LD.

Oncogene. 2016 Aug 18;35(33):4414-21. doi: 10.1038/onc.2015.490. Epub 2016 Jan 4.

10.

p53 Restoration in Induction and Maintenance of Senescence: Differential Effects in Premalignant and Malignant Tumor Cells.

Harajly M, Zalzali H, Nawaz Z, Ghayad SE, Ghamloush F, Basma H, Zainedin S, Rabeh W, Jabbour M, Tawil A, Badro DA, Evan GI, Saab R.

Mol Cell Biol. 2015 Nov 23;36(3):438-51. doi: 10.1128/MCB.00747-15.

11.

p53-based strategy to reduce hematological toxicity of chemotherapy: A proof of principle study.

Ha CS, Michalek JE, Elledge R, Kelly KR, Ganapathy S, Su H, Jenkins CA, Argiris A, Swords R, Eng TY, Karnad A, Crownover RL, Swanson GP, Goros M, Pollock BH, Yuan ZM.

Mol Oncol. 2016 Jan;10(1):148-56. doi: 10.1016/j.molonc.2015.09.004. Epub 2015 Sep 18.

12.

Acute DNA damage activates the tumour suppressor p53 to promote radiation-induced lymphoma.

Lee CL, Castle KD, Moding EJ, Blum JM, Williams N, Luo L, Ma Y, Borst LB, Kim Y, Kirsch DG.

Nat Commun. 2015 Sep 24;6:8477. doi: 10.1038/ncomms9477.

13.

The Trp53 delta proline (Trp53ΔP) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development.

Adams CJ, Yu JS, Mao JH, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A.

Mol Carcinog. 2016 Sep;55(9):1387-96. doi: 10.1002/mc.22377. Epub 2015 Aug 27.

PMID:
26310697
14.

Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.

Weisberg E, Halilovic E, Cooke VG, Nonami A, Ren T, Sanda T, Simkin I, Yuan J, Antonakos B, Barys L, Ito M, Stone R, Galinsky I, Cowens K, Nelson E, Sattler M, Jeay S, Wuerthner JU, McDonough SM, Wiesmann M, Griffin JD.

Mol Cancer Ther. 2015 Oct;14(10):2249-59. doi: 10.1158/1535-7163.MCT-15-0429. Epub 2015 Jul 23.

15.

p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan.

Su H, Ganapathy S, Li X, Yuan ZM, Ha CS.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1116-1122. doi: 10.1016/j.ijrobp.2015.04.003. Epub 2015 Apr 8.

16.

UXT, a novel MDMX-binding protein, promotes glycolysis by mitigating p53-mediated restriction of NF-κB activity.

Qi M, Ganapathy S, Zeng W, Zhang J, Little JB, Yuan ZM.

Oncotarget. 2015 Jul 10;6(19):17584-93.

17.

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.

de Oliveira GA, Rangel LP, Costa DC, Silva JL.

Front Oncol. 2015 Apr 29;5:97. doi: 10.3389/fonc.2015.00097. eCollection 2015. Review.

18.

Broad targeting of resistance to apoptosis in cancer.

Mohammad RM, Muqbil I, Lowe L, Yedjou C, Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, Yang H, Samadi AK, Russo GL, Spagnuolo C, Ray SK, Chakrabarti M, Morre JD, Coley HM, Honoki K, Fujii H, Georgakilas AG, Amedei A, Niccolai E, Amin A, Ashraf SS, Helferich WG, Yang X, Boosani CS, Guha G, Bhakta D, Ciriolo MR, Aquilano K, Chen S, Mohammed SI, Keith WN, Bilsland A, Halicka D, Nowsheen S, Azmi AS.

Semin Cancer Biol. 2015 Dec;35 Suppl:S78-103. doi: 10.1016/j.semcancer.2015.03.001. Epub 2015 Apr 28. Review.

19.

Inhibition of MDM2 by RG7388 confers hypersensitivity to X-radiation in xenograft models of childhood sarcoma.

Phelps D, Bondra K, Seum S, Chronowski C, Leasure J, Kurmasheva RT, Middleton S, Wang D, Mo X, Houghton PJ.

Pediatr Blood Cancer. 2015 Aug;62(8):1345-52. doi: 10.1002/pbc.25465. Epub 2015 Apr 1.

20.

Phenotype specific analyses reveal distinct regulatory mechanism for chronically activated p53.

Kirschner K, Samarajiwa SA, Cairns JM, Menon S, Pérez-Mancera PA, Tomimatsu K, Bermejo-Rodriguez C, Ito Y, Chandra T, Narita M, Lyons SK, Lynch AG, Kimura H, Ohbayashi T, Tavaré S, Narita M.

PLoS Genet. 2015 Mar 19;11(3):e1005053. doi: 10.1371/journal.pgen.1005053. eCollection 2015 Mar.

Supplemental Content

Support Center